BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35670897)

  • 1. Compensated Advanced Chronic Liver Disease in Nonalcoholic Fatty Liver Disease: Two-Step Strategy is Better than Baveno Criteria.
    Elhence A; Anand A; Biswas S; Vaishnav M; Yadav R; Das P; Panwar R; Agarwal S; Gamanagatti S; Kumar R; Shalimar
    Dig Dis Sci; 2023 Mar; 68(3):1016-1025. PubMed ID: 35670897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
    Papatheodoridi M; Hiriart JB; Lupsor-Platon M; Bronte F; Boursier J; Elshaarawy O; Marra F; Thiele M; Markakis G; Payance A; Brodkin E; Castera L; Papatheodoridis G; Krag A; Arena U; Mueller S; Cales P; Calvaruso V; de Ledinghen V; Pinzani M; Tsochatzis EA
    J Hepatol; 2021 May; 74(5):1109-1116. PubMed ID: 33307138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High accuracy of spleen stiffness measurement in diagnosing clinically significant portal hypertension in metabolic-associated fatty liver disease.
    Odriozola A; Puente Á; Cuadrado A; Iruzubieta P; Arias-Loste MT; Redondo C; Rivas C; Fábrega E; Crespo J; Fortea JI
    Liver Int; 2023 Jul; 43(7):1446-1457. PubMed ID: 36912787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
    Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.
    Zhou YJ; Gao F; Liu WY; Wong GL; Mahadeva S; Raihan Nik Mustapha N; Wang XD; Chan WK; Wong VW; Zheng MH
    Aliment Pharmacol Ther; 2021 Aug; 54(4):470-480. PubMed ID: 34152626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of Baveno VI and Expanded-Baveno VI Criteria for predicting gastroesophageal varices in patients with alcoholic and non-alcoholic fatty liver disease.
    Pizzamiglio M; Weicker A; de Terwangne C; Henrion J; Descamps OS; De Vos M
    Acta Gastroenterol Belg; 2022; 85(2):321-329. PubMed ID: 35709776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
    Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
    J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accuracy of non-invasive methods/models for predicting esophageal varices in patients with compensated advanced chronic liver disease secondary to nonalcoholic fatty liver disease.
    Galizzi HO; Couto CA; Taranto DOL; Araújo SIO; Vilela EG
    Ann Hepatol; 2021; 20():100229. PubMed ID: 32745630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of Baveno VII criteria for clinically significant portal hypertension by two-dimensional shear wave elastography.
    He R; Liu C; Grgurevic I; Guo Y; Xu H; Liu J; Liu Y; Wang X; Shi H; Madir A; Podrug K; Zhu Y; Hua Y; Wang K; Wen J; Su M; Zhang Q; Li J; Qi X
    Hepatol Int; 2024 Jun; 18(3):1020-1028. PubMed ID: 38740698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.
    Colecchia A; Ravaioli F; Marasco G; Colli A; Dajti E; Di Biase AR; Bacchi Reggiani ML; Berzigotti A; Pinzani M; Festi D
    J Hepatol; 2018 Aug; 69(2):308-317. PubMed ID: 29729368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
    Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
    Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis.
    Dajti E; Ravaioli F; Zykus R; Rautou PE; Elkrief L; Grgurevic I; Stefanescu H; Hirooka M; Fraquelli M; Rosselli M; Chang PEJ; Piscaglia F; Reiberger T; Llop E; Mueller S; Marasco G; Berzigotti A; Colli A; Festi D; Colecchia A;
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):816-828. PubMed ID: 37478880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive diagnosis and follow-up of portal hypertension.
    Thabut D; Weil D; Bouzbib C; Rudler M; Cassinotto C; Castéra L; Serste T; Oberti F; Ganne-Carrié N; de Lédinghen V; Bourlière M; Bureau C
    Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101767. PubMed ID: 34332128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update.
    Segna D; Mendoza YP; Lange NF; Rodrigues SG; Berzigotti A
    Dig Liver Dis; 2023 Mar; 55(3):326-335. PubMed ID: 36369196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elastography-based screening for esophageal varices in patients with advanced chronic liver disease.
    Paternostro R; Reiberger T; Bucsics T
    World J Gastroenterol; 2019 Jan; 25(3):308-329. PubMed ID: 30686900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of non-invasive diagnosis of CSPH in patients with compensated advanced chronic liver disease according to Baveno VII.
    Song BG; Goh MJ; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Paik SW; Sinn DH
    Liver Int; 2023 Sep; 43(9):1966-1974. PubMed ID: 37288716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.
    Petta S; Sebastiani G; Bugianesi E; Viganò M; Wong VW; Berzigotti A; Fracanzani AL; Anstee QM; Marra F; Barbara M; Calvaruso V; Cammà C; Di Marco V; Craxì A; de Ledinghen V
    J Hepatol; 2018 Oct; 69(4):878-885. PubMed ID: 29802949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
    Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
    Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
    Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
    J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
    Wong YJ; Zhaojin C; Tosetti G; Degasperi E; Sharma S; Agarwal S; Chuan L; Huak CY; Jia L; Xiaolong Q; Saraya A; Primignani M
    Clin Mol Hepatol; 2023 Jan; 29(1):135-145. PubMed ID: 36064306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.